Cancer vaccines by Dalgleish, A G
Vaccination refers to the procedure pioneered by Edward Jenner
(EJ), whereby the immune system is primed to respond rapidly to
an infectious agent, by exposing it to the important antigens of the
infectious agent by using heat-killed or attenuated non-pathogenic
versions. EJ used the biologically naturally attenuated (in
humans), cow pox to provide resistance to small pox. A cancer
vaccine is designed to induce an immune response in a patient who
has developed cancer resistant to conventional treatment cancer or
who has a high probability of developing a recurrence following
adequate treatment. It is reasonable to regard cancer as an infec-
tion that has infected the host without inducing an appropriate
immune response. The reasons that cancer cells are able to evade
the immune system or an effective immune response include:
1. They look like self and bear self-antigens.
2. They actively anergise the immune system to any possible
differentiating (between self and tumour) antigens.
3. They may create an immunosuppressive environment which,
in addition to secreting a number of immunosuppressive
factors, also includes the possession of the equivalent of ‘anti
missile – missile systems’, such as tumour expression of fas-L
which can induce apoptosis of any incoming tumour antigen
specific killer cell (reviewed by Gilboa, 1999; Pawelec, 1999;
Walker et al, 1997).
A number of historical observations strongly suggest that an
appropriate immune response is associated with tumour
regression. These include:
1. William Coley’s observation (over 100 years ago) that severe
septicaemia/erysipelas was occasionally associated with
regression of a number of solid tumours.
2. Spontaneous regression of melanoma deposits associated with
infiltrating immune cells (often mentioned – rarely observed!).
3. The ability to occasionally mimic this activity with cytokine
administration, such as interleukin-2 and interferon as well as
cell-based and peptide-based ‘vaccines’.
4. The association between anti-leukaemia activity and the
development of graft versus host (GVH) disease in post-bone
marrow transplant leukaemia patients. The GVH effect can
clearly be separated from the GV leukaemia effect thus
allowing for therapeutic extrapolation (reviewed by Browning
and Dalgleish, 1996; Dalgleish, 1996; Vile et al 1996).
More recently, the discovery of a board range of antigens which if
delivered appropriately can induce anti-tumour responses, coupled
with an increased understanding of immunological tolerance,
anergy and ignorance, and how to overcome them, has given us
another opportunity to try to harness the immune response against
cancer and to continue where others left off (Boon et al, 1997;
Wang and Rosenberg, 1999).
Coley’s observation that potentially fatal bacterial infections
could induce an effective anti-cancer response in patients with
partially resected tumours led to the development of safer toxins
based on the isolated bacteria cell wall preparations which became
known as Coley’s toxins (Coley, 1991; Nauts and McLaren, 1990).
Coley’s successes were not readily reproducible by others, and his
treatment proved controversial, leading to nearly two decades of
detailed development. Essentially, minor changes in manufacture,
dosage and scheduling appeared to be the difference between
success and failure, which is just as likely to apply to today’s
attempts to develop cancer vaccines. Coley’s toxins were super-
seded by radiotherapy and subsequently chemotherapy following
his retirement. Enthusiasm for immunotherapies and cancer
vaccines has waxed and waned nearly every decade or so
throughout the 20th century, with initial enthusiasm being
dampened by objective clinical studies.
The BCG vaccine has been used to induce anti-cancer immune
responses nearly as long as it has been used against TB
(Nathanson, 1979). In randomized studies it appears to have a
small but not significant difference in the treatment of leukaemia,
melanoma and prostate cancer (Cascinelli et al, 1989; Guinan et al,
1982; Nathanson et al, 1979; Tan and Ho, 1993; Vuvan et al, 1978;
Zuthrie et al, 1980). Its success as an intra-tumoural agent
in the case of melanoma is more impressive, with 20–60%
(depending on which study), of tumours disappearing.
Unfortunately, no significant effect on non-injected metastases is
seen in most cases. Nevertheless, the effect of intravesicular BCG
in superficial bladder cancer is dramatic and the treatment of
choice over chemotherapy by many urologists. It is thought to act
by inducing a specific inflammatory response (Alexandroff et al,
1999; Hurle et al, 1999).
The concept of using tumour cells to treat cancer is far from new
and goes back at least to the 17th century! Throughout the last five
or more decades, both autologous and allogeneic cell lines have
been used to try to treat of number a cancers, particularly
melanoma, renal and colorectal (Morton et al, 1992; Vermorken
et al, 1999). Autologous tumour preparations appear to be
preferred (as they have been in the new era of gene therapy,
involving transfection of cytokines, etc, into cells), with allogeneic
cell lines being tried when the difficulty of raising autologous lines
from enough patients becomes insurmountable. Many studies
using cells also use BCG as an adjuvant (Browning and Dalgleish,
1996; Vile et al, 1996). A large number of studies can be briefly
summarized, in that early studies often showed anecdotal
responses, which failed to translate to significant numbers in
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multiple vaccination protocols (as opposed to one or two injec-
tions). Of all the approaches along these lines, the one developed
by Dr Donald Morton has endured through several decades to the
point where it is now in large multi-centred randomized controlled
trials. The protocol started with BCG and different allogeneic
cells, finally culminating in a three cell-line allogeneic vaccine
given initially with BCG and monthly thereafter, in patients with
metastatic melanoma. Prior to randomization, experience with the
triple-cell vaccine was gained with several hundred patients giving
a two- to three-fold increase in survival at 2 and 5 years. This was
even more pronounced in those patients who could be rendered
disease-free by surgical excision (Hsueh et al, 1998a; 1998b;
Morton et al, 1992). Our own group has recently confirmed this
trend in a smaller phase II study which has now been closed, with
the introduction of the double-blind randomized placebo control
studies for stage III and stage IV patients with metastatic
melanoma (Maraveyas et al, 1999b).
Two developments have led to a resurgence of interest in
developing new cancer vaccines. These are:
1. The ability to transfect cell lines with a variety of
immunomodulatory enhancing genes such as cytokines and
co-stimulatory factors.
2. The identification of a number of new tumour specific/
associated antigens which can be purified for therapeutic use.
The vast majority of all the early anti-cancer gene therapy studies
involve the transfection of mainly interleukin-2 and more recently
GM-CSF into autologous cells. In a number of animal models, it
has clearly been shown that a variety of genes transfected into the
autologous cells will enhance an anti-tumour immune response,
and these include most of the cytokines (with a few exceptions),
growth factors such as GM-CSF, co-stimulatory factors such as
CD 80, CD 86 as well as the expression of HLA class I and class
II. Like their earlier counterparts, however, most investigators
have been frustrated by the difficulty in obtaining available autol-
ogous cells and have looked towards using allogeneic cell lines.
Nevertheless, although the majority of investigators try to match
the allogeneic cell lines in order to have the same HLA class I as
the autologous tumour, our own studies have shown that allo-
geneic cell lines can confer and enhance an anti-tumour activity
compared with autologous cells (Knight et al, 1996; Souberbeille
et al, 1996). It is possible that allogeneic cells are also inducing
some form of graft-versus-tumour activity. The induction of cross-
reactive CTL activity is particularly compelling (Kayaga et al,
1999), a full understanding of which could lead to enhanced
exploitation in order to develop more effective allogeneic-based
therapeutic strategies.
The number of antigens that have been identified as being more
specific to tumour than normal cells has been recently increased
dramatically. Prior to this, clinical studies were mainly focussed
on gangliosides and mucins. A large number of new antigens have
been identified using CTLs from patients who had evidence of
immunological responses to identify peptide sequences which may
be used as therapeutic targets; a technique pioneered by Boon and
colleagues (Boon et al, 1997). Another approach known as
‘SEREX’ involves the use of serum from responding patients to
target humoural epitopes (Tureci et al, 1997).
There are a number of terminologies to define tumour antigens.
The most accurate description overall is tumour associated anti-
gens (TAA) which involves a number of onco-fetal developmental
antigens which may be expressed: tumour developmental antigens
(TDA), e.g. CEA. Some antigens are more specific to tumours
than normal cells, such as tumour specific antigens (TSA), which
can include exogenous viruses that drive the tumour e.g. EBV and
lymphoma, HPV and cancer of the cervix, as well as mutations of
endogenous genes such as oncogenes, e.g. ras and suppressor
genes, e.g. P53 (see Table 1).
A full description of the tumour antigens described to date is
beyond the scope of this review. However, it is worth noting that
gangliosides and mucins which are qualitatively and quantitatively
differentially expressed on cancer cells represent good ‘mono’
antigen targets. They are the subjects of large randomized studies
in melanoma and breast cancer respectively, following encour-
aging phase II trials. (Livingstone et al, 1994; MacLean et al,
1996). Many other tumour antigens can be reduced to peptides and
presented with adjuvants or given with autologous dendritic cells
(DCs) grown ex-vivo. Whatever antigen is identified or selected, it
is unlikely to induce much of an immune response given alone.
It has been known for many years that in order to induce an
immune response it is necessary to use an adjuvant which covers
a broad range of candidates from Freund’s adjuvant, the TB
Vaccine, Bacillus Calmette-Guerin (BCG) through to alum, the
latter of which is the only one with a full licence in humans. Polly
Matzinger would argue that adjuvant is the necessary ‘danger’
signal necessary to alert the immune system which does not
perceive most antigens delivered subcutaneously as dangerous,
and hence will not ‘react’ to them (Fuchs and Matzinger 1996).
With most tumour antigens being essentially derived from self, the
method of presentation and the type of immune response induced
is crucial. The immune response can be predominantly cell-medi-
ated with IL-2, g-IFN and IL-12 being preferentially induced
known as a Th-1 response, or predominantly humoural-mediated
with IL-4, IL-5, IL-6 and IL-10 induction, a Th-2 response. It has
been suspected for some years that cell-mediated responses are
deficient in many cancer patients and more recently that
humoural-dominant responses may be detrimental to some cancers
in this regard. There is now increasing evidence that this is the
case in advanced cancer patients (Goto et al, 1999) including
melanoma and prostate cancer (Maraveyas et al, 1999a; Hrouda
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Table 1 Tumour antigens
Tumour-specific antigens (high affinity, no tolerance)
1. Viral antigens associated with tumour pathogenesis
EBV – lymphoma, nasopharyngeal cancer
HPV – cervix, anal (several other sites suspected)
HBV/HCC – hepatoma (liver cancer)
2. Mutation antigens
Specific tumour and not other tissues
ras, p53 bcr/abl, CDK-4, Caspase 8
Tumour-associated antigens (wide spectrum of affinity and tolerance)
1. Cancer testes (CT) antigens, restricted to:
Primitive germs cells of the testes and following activation of expression in
a number of tumours
MAGE-1–3, GAGE, BAGE, RAGE, PAGE, NY-ESO-1 and many similar
others
2. Differentiation antigens: normal tissues with altered expression on tumour
cells
MART-1/Melay A, gp100, tyrosinase, TRP-1/2 GM2 ganglioside
HER-2/neu, CEA, MUC:
NB This list is exemplary only, several hundred antigens have now been
describedet al, 1998). In addition, we have documented a marked inhibition
of the Th-1 responses in patients with early colorectal cancer
(Duke’s stages A and B) which reverts following surgical removal
(Heriot et al, in press). Alum, historically the most commonly used
adjuvant, is a Th-2 preferential inducer and hence is probably not
ideal for use in most cancer vaccines. Adjuvants which give a
predominate Th-1 response include BCG (which can paradoxically
induce a Th-2 in some people), other mycobacterium such as
M. Vaccae (known as SRL-172), oil/water emulsions (e.g. IDEC-
AF) as well as quil-saponin mixtures (e.g. QS-21). Most of these
adjuvants work best by intradermal as opposed to subcutaneous
injections, as they are taken up by special dendritic cells which
then migrate to the lymph nodes, where they activate the relevant
T cells.
In addition to inducing T-cell responses it would appear that the
isotype of the humoural response is also important. In the melanoma
whole-cell vaccine of Morton and colleagues there is a clear survival
advantage with a dominant IgM (to gangliosides and the TA90
antigen) response, which is lost if the IgG becomes dominant
(Hsueh et al, 1998b) (this is totally the opposite of what would be
expected if vaccinating against an infectious agent). There are a
large number of different adjuvants in pre-clinical studies and these
include cytokines such as IL-2 and IL-12 which may be given
exogenously as well as being transfected into tumour cells.
In addition to adjuvants, enhanced immune responses can be
made using ex vivo cultured (DCs) derived from GM-CSF and
IL-4 and/or TNFa supplemented cultures following pulsing with
antigens prior to re-infusing into patients’ veins or lymph nodes
(Bjorck, 1999). Once again, the details of this approach are critical
as it is also possible to actively tolerize against antigens using
dendritic cells DCs (Ludewig et al, 1999). Antigens present on
cells (i.e. autologous and allogeneic cell-based vaccines) can be
rendered more immunogenic by transfecting with stimulatory
molecules, e.g. B7-1, cytokines such as GM-CSF, IL-2, etc, as well
as combinations thereof. Viral vectors (such as adenovirus) can be
used to present known antigens (e.g. CEA) with cytokine inserts,
e.g. IL-2, either incorporated in a viral vector or as a DNA vaccine.
Both these approaches can then use cultured DCs as the presenta-
tion vehicle, with cells being presented as lysates, and DNA (or
RNA) being transfected directly into the DCs. DCs are the optimal
APC and attempts have been made to form hybridomas to create
an APC full of tumour antigens. Although possible with B cells
and some tumour cell lines, stable fusions are more difficult with
DCs (Scott-Taylor et al, in press). However, further research may
enable this approach to be reduced to practice.
Another interesting approach under the gene therapy label is the
transfer of the HSVtk gene into the tumour using an adenoviral
vector, for instance. Following administration of ganciclovir
which is converted by HSVtk-driven phosphorylation of ganci-
clovir into toxic by-products, an immune-mediated bystander
response is induced in addition to local cell-to-cell transfer of the
toxic by-products. The enhanced immune response is of particular
interest in developing vaccine-based protocols. A number of
similar gene prodrug combinations are also being pursued in this
area in addition to HSVtk/ganciclovir (Perry et al, in press).
Clinical trials have thrown up a number of problems in inducing
an effective anti-tumour immune response. These include:
1. The lack of induction of an appropriate cell-mediated response
(which may be limited by the patient’s own immunogenetics,
especially in the case of peptides).
2. The need for recruitment of effective helper pathways to
expand the initial response, e.g. IL-2-dependent pathways.
3. The lack of development of an appropriate effector response,
e.g. CTL and/or NK response.
4. The presence of a strong immunosuppressor environment
(e.g. the secretion of IL-10, TFG-b, and the expression of 
fas-L) that down-regulates any attacking immune response.
Even if an appropriate antigen-specific response is induced, it may
not last long due to the absence or poor induction of a memory
response. It has been noted with frustration that effective vaccines
need to be given regularly, e.g. monthly, in the presence of even
minimal residual disease. However, even in the absence of tumour-
produced immunosuppressive factors, this is likely to be due to the
fact that most tumour antigens are ‘self’ (or very close), and that
although it is possible to break tolerance, the ability to readily
induce a long-term memory T-cell response would be to induce
potentially catastrophic autoimmunity. It is of note that current
‘cancer vaccines’ rarely induce significant auto-immunity even
when given with strong adjuvants, other than vitiligo patients with
melanoma (a phenomenon which occurs in 5–10% of the popula-
tion who are not vaccinated). It is therefore necessary to consider
regular vaccination in a therapeutic setting, although caution is
necessary as it is possible to over-stimulate and ‘burn out’ the
immune response with some agents such as BCG, which can
destroy any beneficial immune response if given too frequently.
How much antigen with which adjuvant, at which site, how
often, for how long, with what other therapy, for which tumour (or
sub-type) are all unknown quantities in determining an ideal
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Table 2 Clinical trials – melanoma
Randomized Stage ( ) Vaccine Control Status
Livingston (III) GM2-BCG BCG No significant benefit for GM2
ECOG (III) GM2-Q21 HD/IFNa In progress
Progenics (IIA) GM2-QS.21 Observe About to start
(III) GM2-QS.21 Placebo Cancelled
Morton PMCV (III) Three allogeneic cell line + BCG + Placebo In progress
(IV) BCG BCG + Placebo In progress
Ribi Melacine (IV) Two cell lines + Chemotherapy Equivalent
Detox (adjuvant)
Hersey (IIB) (III) Allogeneic lysate Untreated In progress
1 cell
Byrstryn (III) 4 allo (1 xeno) cells Untreated Small numbers; significant bias in
lysates favour of vaccinevaccine strategy. It is clear that minor changes in the starting
conditions can lead to big changes in the outcome, a fact that has
led to speculation elsewhere about applying the ‘chaos theory’ to
vaccine development (Dalgleish 1999). Moreover, if these objec-
tives were readily achieved it may then be necessary to attack the
anti-immune defences of the tumour which include targets such as
TGF-b and IL-10 production and excess CD55 (DAF) and fas-L
expression etc. These approaches may result in additive if not
synergistic effects in outcome.
Optimization of such approaches requires the use of a reliable
laboratory model. The majority of cancer vaccines to date have
been based on the demonstration of anti-tumour efficacy in
animal models. A large number exist and only the naturally non-
immunogenic models pose a major challenge for protection and
Therapeutic strategies, an example is the B16 melanoma model
whose F10 cell line represents a difficult challenge to block
immunologically. Most successful experiments on these models
are protective, in that vaccination has to take place before a tumour
challenge is undertaken. Therapy studies whereby vaccination
commences after tumour challenge are a much harder hurdle to
overcome. We have used several of these models to demonstrate
that allogeneic cell vaccination is able to induce stronger protec-
tive responses than autologous cell vaccines (Knight et al, 1996;
Hrouda et al, submitted; Souberbielle et al, 1996; 1998). This
effect extends to the two known rat prostate cancer models,
Dunning and the Lobund-Wistar, whereby cells from the former
confer an 80% protection in the latter (Hrouda et al, submitted).
These models have also been used to demonstrate that optimal
adjuvants can perform as well as cytokine transfected cells
(Souberbielle et al, 1996) and that GM-CSF transfected allogeneic
cells can induce an effective therapeutic response by inducing
cross-reacting CTL response (Kayaga et al, 1999). Other encour-
aging approaches include heat-shock protein/tumour antigen
complexes (Srivastava and Udonon, 1994), tumour-cell antigen-
presenting cell hybridomas, DNA and RNA vaccines given intra-
muscularly or transfected into dendritic cells, as well as antigens
given as peptides or encoded in a viral/bacterial vector which may
also be given with DCs.
A large number of clinical trials involving cancer vaccines are
currently ongoing (see Tables 2, 3 and 4) Many of these have
focused on melanoma, where encouraging phase II studies have
led to randomized trials for gangliosides and whole allogeneic
(Morton MCV) cell lines. Trials with single peptides have been
disappointing and multiple peptides are more encouraging,
although ‘help’ in the form of IL-2 or presentation with DCs
appears to be required in most cases (Rosenberg et al, 1998). As so
many melanoma (and other cell-type tumour antigens) are shared
with other tumour types, widespread application of these
approaches to other tumours, such as renal, prostate, lung, breast,
pancreas and colorectal, are being tried. However, the general
principles established in pre-clinical and early melanoma studies
will probably continue to apply, in that the immune response is
difficult to induce in advanced disease and cancer vaccines work
best in the adjuvant or minimal residual disease setting. The two
most intensive areas of expansion regarding clinical trials at the
present time are the use of dendritic cells and the role of
DNA/RNA vaccines. They can, of course, easily be combined
with RNA/DNA transfection of DCs already in progress. The ex
vivo growth of DCs (with at least three possible progenitor types)
inherently carries the potential for considerable variability
following culture in GM-CSF plus IL-4/INFa. Many questions
remain unanswered, such as the optimal time to harvest, what to
pulse with and which route to use for presentation, e.g. intravenous
or intranodal. Occasional dramatic responses have been seen (in a
number of tumour types) which are not reliably reproducible, and
the reasons for this require further elucidation. The role of the
CD40 and FLT-3 ligands look like an increasingly important area
of research in this regard (Di Nicola et al, 1998; French et al, 1999;
Siena et al, 1995). DNA vaccines allow for the bespoke manufac-
ture of private idiotypes as seen in lymphomas. A recent study has
shown that such vaccinations given to bulk reduced, yet
‘lymphoma PCR-positive patients’ could be rendered PCR-nega-
tive in 8/11 lymphoma patients (Bendandi et al, 1999). Previous
studies in advanced disease were disappointing due to the marked
immunosuppression seen in patients with advanced lymphomas.
It will, therefore, be necessary to integrate cancer vaccines into
a sequentially managed therapy (SMT) programme to treat cancer
patients, which will include the use of other modalities such as
radical surgery and chemotherapy for debulking disease and even
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Table 3 Examples of phase II clinical studies in melanoma
Peptides Transfected cells




Peptides + IL2 Auto + Allo HLA-B7
Peptides + dendritic cells Combinations 
Antigens in virus vectors eg. IL-2 + B7
Antigens as DNA
Non-specific; SRL-172
Table 4 Other clinical trials/studies
Phase Status
Other vaccine-based studies:
Prostate: Cells (auto/allo) + GM-CSF IP
Peptides + DC IP
Allo cells + adjuvant IP
Gangliosides IP
Colorectal studies/pancreas
Autologous cells + BCG SR [Ref] Vermorken 
et al, 1999
Viral vector + CEA P
105 AD7 II & III NS
Cells and adjuvant P
Ras mutant peptides + DCs IP
Breast cancer:
Sialyl Tn/MUC-1. IP. (peptides and in vectors) IP
Neu/HER and anti-idiotype IP
Lung
Anti-GD3 (BEC + BCG) III EORTC IP
Chemo + SRL-172 III IP
Autologous cells II IP




DCs + cell lysates IP
Legend: IP = in progress; P = planning stage; SR = significant response;
NS = non-significant response.the incorporation of radiotherapy to enhance autologous tumour
necrosis, and hence antigen presentation to stimulate the immune
system. Vaccines may help other treatments to work better than
alone. For instance, our own experience regarding the enhanced
susceptibility of vaccine patients with melanoma to radiotherapy,
which was thought to be an original observation until several such
reports were uncovered (Cameron et al, 1990). Hence, our means
of assessment will need to change regarding the use of vaccines
used to treat patients with non-debulkable disease, where the lack
of complete and partial responses often gives way to static disease,
improved quality of life and prolonged survival, which within such
programmes are realistic goals for non-toxic outpatient treatments.
Cytokines and monoclonal antibodies may beneficially be incor-
porated into SMT, which in the case of Herceptin could be comple-
mented by ongoing anti-idiotype vaccination against the HER
receptor.
Most solid cancers arise out of areas of chronic inflammation,
which are histologically if not clinically evident, e.g. lung, oesoph-
agus, stomach, liver, colorectal, cervix, etc. Chronic inflammation
whether or not induced by cigarettes, helicobacter, hepatitis B, bile
salts, etc, is associated with a depression of Th-1 responses and an
increase in angiogenesis, both features of wound healing and
pregnancy. Such a state allows immunological sanctuary for
the obvious reasons that if cell-mediated responses were not
suppressed in these conditions, T-cells would react with self
tissues with resultant autoimmunity, and in the case of pregnancy
the fetus would be rejected. Long-term Th-1 suppression allows
oncogen mutations to survive as they are not immediately elimi-
nated by CTLs, and the segmental progression to a malignant cell
can progress unchecked (O’Byrne et al, in press). The enhanced
angiogenesis can enable distance spread and prolong immunosup-
pression. Thus if this is indeed the case in vivo, cancer vaccines
may well benefit from co-treatment with anti-angiogenic treat-
ments and anti-inflammatory agents. There are obvious implica-
tions for prevention. One fact that supports this speculation is the
unexpected drop in the incidence of colorectal cancer in patients
taking daily aspirin (Thun, 1997).
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